Buscar
IRIDEX Corp
IRIXAñadir a la lista de seguimiento
1.130USD
-0.040-3.42%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
19.66MCap. mercado
PérdidaP/E TTM
Más Datos de IRIDEX Corp Compañía
IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Información de IRIDEX Corp
Símbolo de cotizaciónIRIX
Nombre de la empresaIRIDEX Corp
Fecha de salida a bolsaFeb 16, 1996
Director ejecutivoMercer (Patrick)
Número de empleados93
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 16
Dirección1212 Terra Bella Ave
CiudadMOUNTAIN VIEW
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94043
Teléfono16509404700
Sitio Webhttps://www.iridex.com/
Símbolo de cotizaciónIRIX
Fecha de salida a bolsaFeb 16, 1996
Director ejecutivoMercer (Patrick)
Ejecutivos de IRIDEX Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. William M. (Will) Moore, Jr.
Mr. William M. (Will) Moore, Jr.
Independent Director
Independent Director
402.00K
--
Mr. Patrick Mercer
Mr. Patrick Mercer
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
162.07K
-2.46%
Mr. Romeo R. Dizon
Mr. Romeo R. Dizon
Chief Financial Officer
Chief Financial Officer
110.78K
+6.57%
Ms. Beverly A. Huss
Ms. Beverly A. Huss
Independent Director
Independent Director
92.64K
--
Mr. Scott A. Shuda, J.D.
Mr. Scott A. Shuda, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Yu Hao (Nick) Chen
Mr. Yu Hao (Nick) Chen
Independent Director
Independent Director
--
--
Mr. Bassem Bouhabib
Mr. Bassem Bouhabib
Vice President - International Sales
Vice President - International Sales
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. William M. (Will) Moore, Jr.
Mr. William M. (Will) Moore, Jr.
Independent Director
Independent Director
402.00K
--
Mr. Patrick Mercer
Mr. Patrick Mercer
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
162.07K
-2.46%
Mr. Romeo R. Dizon
Mr. Romeo R. Dizon
Chief Financial Officer
Chief Financial Officer
110.78K
+6.57%
Ms. Beverly A. Huss
Ms. Beverly A. Huss
Independent Director
Independent Director
92.64K
--
Mr. Scott A. Shuda, J.D.
Mr. Scott A. Shuda, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Yu Hao (Nick) Chen
Mr. Yu Hao (Nick) Chen
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de IRIDEX Corp?
Los cinco principales accionistas de IRIDEX Corp son: Mr. William M. (Will) Moore, Jr.
¿Cuántas instituciones poseen acciones de IRIDEX Corp (IRIX)?
A fecha de 2026Q1, 52 instituciones poseen acciones de IRIDEX Corp, con un valor de mercado combinado de aproximadamente 3.69M, lo que representa el 21.29% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 278304.00.
¿Cuál es la mayor fuente de ganancias de IRIDEX Corp?
El 2026Q1, el segmento empresarial Retina generó la ganancia más alta para IRIDEX Corp, ascendiendo a 6.70M y representando el 53.65% de la ganancia total.